Stock ALTME TME PHARMA N.V.
Add to a list
To use this feature you must be a member
Log inSign up

Financials TME Pharma N.V.

Equities

ALTME

NL0015000YE1

Biotechnology & Medical Research

Market Closed - Euronext Paris
Other stock markets
 11:35:22 2024-04-26 EDT 		5-day change 1st Jan Change
0.249 EUR +0.20% Intraday chart for TME Pharma N.V. -0.99% +8.26%
04-25 TME Pharma N.V. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
04-23 TME Pharma N.V. Announces 33% of Patients Receiving NOX-A12 in Combination With Bevacizumab and Radiotherapy Achieve Two-Year Survival in GLORIA Phase 1/2 Trial in Brain Cancer CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 10.27 7.587 24.37 17.44 1.653 1.22
Enterprise Value (EV) 1 6.062 6.331 14.17 10.42 1.105 0.2535
P/E ratio -0.38 x -7.28 x -1.75 x -1.07 x -0.09 x -0.17 x
Yield - - - - - -
Capitalization / Revenue - 49,268,565 x 696,168,657 x 528,495,364 x - 71,735,824 x
EV / Revenue - 41,112,721 x 404,825,800 x 315,889,303 x - 14,912,294 x
EV / EBITDA -1.32 x -1.57 x -2.44 x -0.78 x -0.09 x -0.05 x
EV / FCF 2.59 x -1.06 x -3.46 x -1.42 x -0.15 x -0.05 x
FCF Yield 38.7% -94.7% -28.9% -70.6% -665% -1,982%
Price to Book -3.95 x -4.12 x 3.43 x 3.86 x -1.65 x -5.23 x
Nbr of stocks (in thousands) 101 130 434 745 1,360 5,302
Reference price 2 102.0 58.20 56.20 23.40 1.216 0.2300
Announcement Date 19-04-12 20-04-22 21-04-28 22-04-22 23-04-24 24-04-25
1EUR in Million2EUR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022
Net sales - 0.154 0.035 0.033 -
EBITDA 1 -4.593 -4.044 -5.807 -13.44 -11.99
EBIT 1 -4.616 -4.064 -5.824 -13.46 -12.01
Operating Margin - -2,638.96% -16,640% -40,790.91% -
Earnings before Tax (EBT) 1 -10.74 -0.86 -10.41 -14.45 -15.13
Net income 1 -10.73 -0.861 -10.4 -14.45 -15.13
Net margin - -559.09% -29,728.57% -43,793.94% -
EPS 2 -269.8 -8.000 -32.16 -21.90 -12.86
Free Cash Flow 1 2.345 -5.997 -4.091 -7.361 -7.349
FCF margin - -3,894.07% -11,688.21% -22,305.3% -
FCF Conversion (EBITDA) - - - - -
FCF Conversion (Net income) - - - - -
Dividend per Share - - - - -
Announcement Date 19-04-12 20-04-22 21-04-28 22-04-22 23-04-24
1EUR in Million2EUR
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022
Net Debt 1 - - - - -
Net Cash position 1 4.2 1.26 10.2 7.02 0.55
Leverage (Debt/EBITDA) - - - - -
Free Cash Flow 1 2.34 -6 -4.09 -7.36 -7.35
ROE (net income / shareholders' equity) 329% 38.6% -356% -237% -937%
ROA (Net income/ Total Assets) -106% -81.3% -58.8% -82.4% -100%
Assets 1 10.13 1.059 17.7 17.54 15.12
Book Value Per Share 2 -25.80 -14.10 16.40 6.060 -0.7400
Cash Flow per Share 2 42.70 10.60 21.90 12.70 2.690
Capex 1 0.01 0.02 0.04 0.01 0.02
Capex / Sales - 10.39% 111.43% 42.42% -
Announcement Date 19-04-12 20-04-22 21-04-28 22-04-22 23-04-24
1EUR in Million2EUR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Chiffre d''affaires - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
TME PHARMA N.V. Stock TME Pharma N.V.
+8.26% 7.56M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. ALTME Stock
  4. Financials TME Pharma N.V.